Avacta has announced the successful completion of patient dosing in the first cohort of the two weekly dosing regimen in Arm 2 of the Phase 1a tolerability clinical study of AVA6000 with no adverse safety signals. Three patients have now been dosed in the second cohort. The company has also announced the initiation of a sub-study with SOFIE Biosciences (SOFIE) to better characterise the entire spread of cancer and related levels of FAP in selected patients with a view to identifying the target cancers most likely to respond to AVA6000 for when the Phase 1 study proceeds to test for efficacy in Phase 1b. Avacta remains on track to commence the dose expansion Phase 1b efficacy study and to present further data from the AVA6000 trial in 2H24.
24 May 2024
Avacta Group | AVA6000 positive Phase 1a Arm 2 update
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Avacta Group | AVA6000 positive Phase 1a Arm 2 update
Avacta Group PLC (AVCT:LON) | 40.2 0.1 0.6% | Mkt Cap: 144.5m
- Published:
24 May 2024 -
Author:
Colin Smith -
Pages:
4
Avacta has announced the successful completion of patient dosing in the first cohort of the two weekly dosing regimen in Arm 2 of the Phase 1a tolerability clinical study of AVA6000 with no adverse safety signals. Three patients have now been dosed in the second cohort. The company has also announced the initiation of a sub-study with SOFIE Biosciences (SOFIE) to better characterise the entire spread of cancer and related levels of FAP in selected patients with a view to identifying the target cancers most likely to respond to AVA6000 for when the Phase 1 study proceeds to test for efficacy in Phase 1b. Avacta remains on track to commence the dose expansion Phase 1b efficacy study and to present further data from the AVA6000 trial in 2H24.